Basic Information
| LncRNA/CircRNA Name | ANRASSF1 |
| Synonyms | NA |
| Region | GRCh38_3:50337511-50338300 |
| Ensemble | ENSG00000281358 |
| Refseq | NR_109831 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | RT-PCR etc. |
| Sample | Three mammary epithelial cell lines (MECs: 184A1 and 184B5, both chemically transformed and MCF10A derived from benign fibrocystic disease) and 10 breast cancer cell lines (BCCs: BT-483, BT-549, Hs578T, MCF7, MDA-MB-134, MDAMB-231, MDA-MB-415, MDA-MB-453, MDA-MB-468, and SK-BR-3) |
| Expression Pattern | up-regulated |
| Function Description | RASSF1C remained unmethylated and RASSF1A was hypermethylated at high frequencies in 75 primary breast cancers, and also in a panel of three mammary epithelial cells (MEC) and 10 breast cancer cell lines (BCC). Although RASSF1C was expressed in all cell lines, only two of them expressed the transcript RASSF1A. ANRASSF1 expression levels were increased in six BCCs. In vitro induced demethylation with 5-Aza-2'-deoxicytydine (5-Aza-dC) resulted in up-regulation of RASSF1A and an inverse correlation with ANRASSF1 relative abundance in BCCs. However, increased levels of both transcripts were observed in two MECs (184A1 and MCF10A) after treatment with 5-Aza-dC. |
| Pubmed ID | 31062660 |
| Year | 2019 |
| Title | The long non-coding RNA ANRASSF1 in the regulation of alternative protein-coding transcripts RASSF1A and RASSF1C in human breast cancer cells: implications to epigenetic therapy |
External Links
| Links for ANRASSF1 | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |